RDPTF
Radiopharm Theranostics Limited
Price Chart
Latest Quote
$0.01
+0.00 (+0.00%)
Current Price
| Previous Close | $0.01 |
| Open | $0.00 |
| Day High | $0.00 |
| Day Low | $0.00 |
| Volume | 10,000 |
Stock Information
Note: Financial values converted from AUD to USD
| Shares Outstanding | 4.71B |
| Cash Equivalents | $2.91M |
| Revenue | $9.05M |
| Net Income | $-40.05M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $31.37M |
| EPS (TTM) | $-0.01 |
| Exchange | PNK |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $22.40M |
| Sales | $9.05M |
| Income | $-40.05M |
| Book/sh | $0.00 |
| Cash/sh | $0.00 |
| Employees | 14 |
Financial Ratios
| Quick Ratio | 1.14 |
| Current Ratio | 1.16 |
Returns & Margins
| ROA | -45.15% |
| ROE | -174.71% |
| Gross Margin | -266.89% |
| Operating Margin | -400.35% |
Ownership
| Insider Ownership | 21.40% |
| Institutional Ownership | 8.30% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| P/S | 2.44 |
| P/B | 1.35 |
Analyst Data
| Recommendation | none |
Technical Indicators
| SMA20 | $0.01 |
| SMA50 | $0.01 |
| SMA200 | $0.01 |
| RSI | nan |
| Shares Float | 3.59B |
| Volatility | 0.86 |
Performance History
| Week | +0.00% |
| Month | +0.00% |
| Quarter | -33.40% |
| 6 Months | -66.70% |
| YTD | -66.70% |
| Year | -66.70% |
| 3 Years | -92.60% |
| 10 Years | -92.60% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-10-30 | $0.01 | 0 |
| 2026-10-29 | $0.01 | 0 |
| 2026-10-28 | $0.01 | 0 |
| 2026-10-27 | $0.01 | 0 |
| 2026-10-26 | $0.01 | 0 |
| 2026-10-23 | $0.01 | 0 |
| 2026-10-22 | $0.01 | 0 |
| 2026-10-21 | $0.01 | 0 |
| 2026-10-20 | $0.01 | 0 |
| 2026-10-19 | $0.01 | 0 |
| 2026-10-16 | $0.01 | 0 |
| 2026-10-15 | $0.01 | 0 |
| 2026-10-14 | $0.01 | 0 |
| 2026-10-13 | $0.01 | 0 |
| 2026-10-12 | $0.01 | 0 |
| 2026-10-09 | $0.01 | 0 |
| 2026-10-08 | $0.01 | 0 |
| 2026-10-07 | $0.01 | 0 |
| 2026-10-06 | $0.01 | 0 |
| 2026-10-05 | $0.01 | 0 |
| 2026-10-02 | $0.01 | 0 |
| 2026-10-01 | $0.01 | 0 |
| 2026-09-30 | $0.01 | 0 |
About Radiopharm Theranostics Limited
Radiopharm Theranostics Limited a clinical-stage radiotherapeutics company, engages in the development of radiopharmaceutical products for diagnostic and therapeutic uses in areas with high unmet medical needs in the United States. The company develops RAD101, a pivalate brain metastasis diagnostic; RAD102, a pivalate therapeutic; RAD201a, a Nano-mAb HER-2 breast diagnostic; RAD202, a Nano-mAb HER-2 breast therapeutic; RAD203, a Nano-mAb PDL1 non-small cell lung diagnostic; and RAD204, a Nano-mAb PDL1 non-small cell lung therapeutic. It is also developing RAD301 and RAD302, which are AvÃ6-Integrin pancreatic diagnostic and therapeutic products; RAD401, a PSA-mAb prostate cancer diagnostic; and RAD402, a PSA-mAb prostate cancer therapeutic. The company was incorporated in 2021 and is based in Carlton, Australia.
đ° Latest News
No news articles available at the moment. Check back later for updates on RDPTF.
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $3,594,146 | $0 | $0 | - |
| Cost Of Revenue | $3,594,146 | $0 | $0 | - |
| Total Revenue | $3,633,422 | $299,228 | $292,359 | $8,831 |
| Operating Revenue | $3,633,422 | $299,228 | $292,359 | $8,831 |
| Expenses | ||||
| Interest Expense | $65,300 | $642,888 | $86,091 | $9,349,739 |
| Total Expenses | $38,274,157 | $37,473,113 | $31,982,960 | $19,925,183 |
| Other Income Expense | $-3,931,539 | $-10,453,185 | $-2,941,532 | $-1,028,491 |
| Net Non Operating Interest Income Expense | $333,109 | $-225,685 | $58,944 | $-9,349,739 |
| Total Other Finance Cost | $489,787 | $-366,719 | - | - |
| Interest Expense Non Operating | $65,300 | $642,888 | $86,091 | $9,349,739 |
| Operating Expense | $34,680,011 | $37,473,113 | $31,982,960 | $19,925,183 |
| Other Operating Expenses | $-9,368,544 | $-1,292,578 | $-5,917,484 | $1,606,799 |
| General And Administrative Expense | $16,526,030 | $15,671,890 | $15,262,382 | $11,212,148 |
| Other Non Operating Income Expenses | - | $-7,567,780 | $5,917,484 | $-1,028,491 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-38,342,457 | $-47,949,119 | $-34,611,194 | $-30,338,979 |
| Net Interest Income | $333,109 | $-225,685 | $58,944 | $-9,349,739 |
| Interest Income | $888,196 | $50,484 | $145,035 | - |
| Normalized Income | $-35,590,380 | $-40,631,890 | $-32,552,122 | $-29,619,035 |
| Net Income From Continuing And Discontinued Operation | $-38,342,457 | $-47,949,119 | $-34,611,194 | $-30,338,979 |
| Total Operating Income As Reported | $-38,173,865 | $-47,209,867 | $-34,487,098 | - |
| Net Income Common Stockholders | $-38,342,457 | $-47,949,119 | $-34,611,194 | $-30,338,979 |
| Net Income | $-38,342,457 | $-47,949,119 | $-34,611,194 | $-30,338,979 |
| Net Income Including Noncontrolling Interests | $-38,342,457 | $-47,949,119 | $-34,611,194 | $-30,338,979 |
| Net Income Continuous Operations | $-38,342,457 | $-47,949,119 | $-34,611,194 | $-30,338,979 |
| Pretax Income | $-38,239,165 | $-47,852,755 | $-34,573,189 | $-30,294,582 |
| Special Income Charges | $-4,069,680 | $-10,548,149 | $-2,684,281 | - |
| Interest Income Non Operating | $888,196 | $50,484 | $145,035 | - |
| Operating Income | $-34,640,735 | $-37,173,885 | $-31,690,601 | $-19,916,352 |
| Depreciation Amortization Depletion Income Statement | $7,331 | $7,534 | $6,553 | $2,981,484 |
| Depreciation And Amortization In Income Statement | $7,331 | $7,534 | $6,553 | $2,981,484 |
| Depreciation Income Statement | $7,331 | $7,534 | $6,553 | $1,171 |
| Gross Profit | $39,276 | $299,228 | $292,359 | $8,831 |
| Amortization Of Intangibles Income Statement | - | $3,118,752 | $3,289,979 | $2,980,313 |
| Per Share | ||||
| Diluted EPS | $-0.02 | $-0.12 | $-0.11 | $-0.15 |
| Basic EPS | $-0.02 | $-0.12 | $-0.11 | $-0.15 |
| Other | ||||
| Tax Effect Of Unusual Items | $-1,179,462 | $-3,135,956 | $-882,460 | $-308,547 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-34,234,995 | $-36,749,148 | $-31,539,013 | $-16,934,868 |
| Total Unusual Items | $-3,931,539 | $-10,453,185 | $-2,941,532 | $-1,028,491 |
| Total Unusual Items Excluding Goodwill | $-3,931,539 | $-10,453,185 | $-2,941,532 | $-1,028,491 |
| Reconciled Depreciation | $7,331 | $7,534 | $6,553 | $2,981,484 |
| EBITDA (Bullshit earnings) | $-38,166,534 | $-47,202,333 | $-34,480,545 | $-17,963,359 |
| EBIT | $-38,173,865 | $-47,209,867 | $-34,487,098 | $-20,944,843 |
| Diluted Average Shares | $2,085,402,784 | $386,460,137 | $323,816,539 | $198,514,296 |
| Basic Average Shares | $2,081,058,451 | $386,460,137 | $323,816,539 | $198,514,296 |
| Diluted NI Availto Com Stockholders | $-38,342,457 | $-47,949,119 | $-34,611,194 | - |
| Tax Provision | $103,292 | $96,364 | $38,005 | $44,397 |
| Gain On Sale Of Ppe | $0 | $-1,687,791 | $0 | - |
| Restructuring And Mergern Acquisition | $4,069,680 | $8,860,358 | $2,684,281 | - |
| Gain On Sale Of Security | $138,141 | $94,964 | $-257,251 | $-1,028,491 |
| Research And Development | $27,515,194 | $23,086,267 | $22,631,509 | $4,124,752 |
| Selling General And Administration | $16,526,030 | $15,671,890 | $15,262,382 | $11,212,148 |
| Other Gand A | $4,404,771 | $3,223,724 | $5,389,768 | $1,969,617 |
| Insurance And Claims | $105,762 | $359,209 | $685,413 | - |
| Salaries And Wages | $12,015,497 | $12,088,957 | $9,187,201 | $9,242,531 |
| Impairment Of Capital Assets | - | $1,478,892 | $3,100,000 | - |
| Amortization | - | $3,118,752 | $3,289,979 | $2,980,313 |
Fetched: 2026-02-02
Balance Sheet (Annual)
| Metric | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $-1,782,418 | $-20,964,726 | $-14,156,746 | $6,887,411 |
| Total Assets | $86,481,876 | $72,036,345 | $74,949,668 | $83,381,291 |
| Total Non Current Assets | $46,627,888 | $49,188,085 | $58,649,564 | $56,116,886 |
| Investmentin Financial Assets | $0 | $40,000 | - | - |
| Goodwill And Other Intangible Assets | $46,574,422 | $49,087,288 | $58,541,234 | $56,075,308 |
| Other Intangible Assets | $46,574,422 | $49,087,288 | $58,541,234 | $56,075,308 |
| Current Assets | $39,853,988 | $22,848,260 | $16,300,104 | $27,264,405 |
| Other Current Assets | $337,093 | $288,215 | $133,130 | $228,818 |
| Assets Held For Sale Current | $0 | $2,997,592 | - | - |
| Receivables | $10,400,060 | $987,413 | $4,467,908 | $56,482 |
| Other Receivables | $228,528 | $184,425 | $4,363,200 | - |
| Taxes Receivable | $10,171,532 | $802,988 | - | - |
| Cash Cash Equivalents And Short Term Investments | $29,116,835 | $18,575,040 | $11,699,066 | $26,979,105 |
| Cash And Cash Equivalents | $29,116,835 | $18,575,040 | $11,699,066 | $26,979,105 |
| Cash Financial | $29,116,835 | $18,575,040 | $11,699,066 | $26,979,105 |
| Other Non Current Assets | - | $40,000 | $40,000 | $40,000 |
| Accounts Receivable | - | $802,988 | $104,708 | $56,482 |
| Gross Accounts Receivable | - | $802,988 | $104,708 | $56,482 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $43,609,972 | $44,683,059 | $29,370,243 | $20,418,572 |
| Total Non Current Liabilities Net Minority Interest | $28,676,987 | $27,107,289 | $16,141,046 | $12,539,945 |
| Other Non Current Liabilities | $28,676,987 | $27,107,289 | $15,971,844 | $12,387,498 |
| Tradeand Other Payables Non Current | $0 | $0 | $169,202 | $152,447 |
| Non Current Deferred Liabilities | $0 | $0 | - | - |
| Current Liabilities | $14,932,985 | $17,575,770 | $13,229,197 | $7,878,627 |
| Other Current Liabilities | $3,421,337 | $3,963,305 | $7,820,702 | $5,632,168 |
| Current Deferred Liabilities | $1,720,551 | $2,355,884 | - | - |
| Payables And Accrued Expenses | $9,340,993 | $10,856,793 | $5,119,465 | $2,153,318 |
| Payables | $6,590,331 | $9,176,351 | $5,119,465 | $2,153,318 |
| Other Payable | $242,934 | $2,741,827 | $2,162,937 | $963,678 |
| Accounts Payable | $6,347,397 | $6,434,524 | $2,956,528 | $1,189,640 |
| Equity | ||||
| Common Stock Equity | $44,792,004 | $28,122,562 | $44,384,488 | $62,962,719 |
| Total Equity Gross Minority Interest | $42,871,904 | $27,353,286 | $45,579,425 | $62,962,719 |
| Stockholders Equity | $44,792,004 | $28,122,562 | $44,384,488 | $62,962,719 |
| Other Equity Interest | $849,544 | $849,544 | $2,146,566 | - |
| Gains Losses Not Affecting Retained Earnings | $13,116,919 | $37,930,072 | $10,361,457 | $7,028,105 |
| Other Equity Adjustments | $13,116,919 | $37,930,072 | $10,361,457 | $7,028,105 |
| Retained Earnings | $-145,732,952 | $-111,338,770 | $-65,353,864 | $-30,824,169 |
| Other | ||||
| Ordinary Shares Number | $2,364,949,502 | $460,367,051 | $359,265,292 | $279,769,546 |
| Share Issued | $2,364,949,502 | $460,367,051 | $359,265,292 | $279,769,546 |
| Tangible Book Value | $-1,782,418 | $-20,964,726 | $-14,156,746 | $6,887,411 |
| Invested Capital | $44,792,004 | $28,122,562 | $44,384,488 | $62,962,719 |
| Working Capital | $24,921,003 | $5,272,490 | $3,070,907 | $19,385,778 |
| Total Capitalization | $44,792,004 | $28,122,562 | $44,384,488 | $62,962,719 |
| Minority Interest | $-1,920,100 | $-769,276 | $1,194,937 | - |
| Capital Stock | $176,558,493 | $100,681,716 | $97,230,329 | $86,758,783 |
| Common Stock | $176,558,493 | $100,681,716 | $97,230,329 | $86,758,783 |
| Current Deferred Revenue | $1,720,551 | $0 | - | - |
| Pensionand Other Post Retirement Benefit Plans Current | $450,104 | $399,788 | $289,030 | $93,141 |
| Current Accrued Expenses | $2,750,662 | $1,680,442 | - | - |
| Investments And Advances | $0 | $40,000 | - | - |
| Net PPE | $53,466 | $60,797 | $68,330 | $1,578 |
| Foreign Currency Translation Adjustments | - | $-544,337 | - | - |
| Available For Sale Securities | - | $40,000 | - | - |
| Gross PPE | - | $60,797 | $68,330 | $1,578 |
| Machinery Furniture Equipment | - | $60,797 | $68,330 | $1,578 |
Fetched: 2026-02-02
Cash Flow Statement (Annual)
| Metric | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-36,645,477 | $-22,975,935 | $-24,732,479 | $-38,254,304 |
| Operating Activities | ||||
| Cash Flowsfromusedin Operating Activities Direct | $-36,645,477 | $-22,975,935 | $-23,201,798 | $-9,915,654 |
| Classesof Cash Receiptsfrom Operating Activities | $5,353,973 | $5,112,301 | $1,847,555 | $-9,915,654 |
| Other Cash Paymentsfrom Operating Activities | - | $4,851,839 | $1,555,196 | - |
| Other Cash Receiptsfrom Operating Activities | - | $4,851,839 | $1,555,196 | - |
| Investing Activities | ||||
| Investing Cash Flow | $1,770,598 | $-320,000 | $-1,530,681 | $-28,369,819 |
| Cash Flow From Continuing Investing Activities | $1,770,598 | $-320,000 | $-1,530,681 | $-28,369,819 |
| Net Other Investing Changes | $-1,226,994 | $-320,000 | - | $-40,000 |
| Capital Expenditure | - | - | $-1,530,681 | $-28,338,650 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $53,977,902 | $29,645,526 | $10,072,555 | $70,000,000 |
| Financing Cash Flow | $45,431,548 | $30,196,945 | $9,217,791 | $65,110,114 |
| Cash Flow From Continuing Financing Activities | $45,431,548 | $30,196,945 | $9,217,791 | $65,110,114 |
| Net Other Financing Charges | $-6,646,354 | $-1,650,771 | $-854,764 | $-4,830,886 |
| Net Common Stock Issuance | $53,977,902 | $29,645,526 | $10,072,555 | $70,000,000 |
| Common Stock Issuance | $53,977,902 | $29,645,526 | $10,072,555 | $70,000,000 |
| Repurchase Of Capital Stock | - | $-1,533,771 | $-854,764 | $-4,830,886 |
| Other | ||||
| Repayment Of Debt | $-1,900,000 | $-5,167,000 | $0 | $-69,000 |
| Issuance Of Debt | $0 | $7,369,190 | $0 | $10,000 |
| End Cash Position | $29,116,835 | $18,575,040 | $11,699,066 | $26,979,105 |
| Beginning Cash Position | $18,575,040 | $11,699,066 | $26,979,105 | $27,091 |
| Effect Of Exchange Rate Changes | $-14,874 | $-25,036 | $234,649 | $127,373 |
| Changes In Cash | $10,556,669 | $6,901,010 | $-15,514,688 | $26,824,641 |
| Net Issuance Payments Of Debt | $-1,900,000 | $2,202,190 | $0 | $-59,000 |
| Net Long Term Debt Issuance | $-1,900,000 | $2,202,190 | $0 | $-59,000 |
| Long Term Debt Payments | $-1,900,000 | $-5,167,000 | $0 | $-69,000 |
| Long Term Debt Issuance | $0 | $7,369,190 | $0 | $10,000 |
| Net Intangibles Purchase And Sale | $2,997,592 | $0 | $-1,485,375 | $-28,335,901 |
| Net PPE Purchase And Sale | $0 | $0 | $-45,306 | $-2,749 |
| Purchase Of PPE | $0 | $0 | $-45,306 | $-2,749 |
| Taxes Refund Paid Direct | $0 | $4,851,839 | $1,555,196 | - |
| Interest Received Direct | $800,309 | $50,484 | $145,035 | - |
| Classesof Cash Payments | $-42,799,759 | $-28,138,720 | $-25,194,388 | - |
| Paymentsto Suppliersfor Goodsand Services | $-42,799,759 | $-28,138,720 | $-25,194,388 | - |
| Receiptsfrom Customers | $5,353,973 | $260,462 | $292,359 | $-9,915,654 |
| Common Stock Payments | - | $-1,533,771 | $-854,764 | $-4,830,886 |
| Purchase Of Intangibles | - | - | $-1,485,375 | $-28,335,901 |
| Interest Received Cfi | - | - | - | $8,831 |
Fetched: 2026-02-02